Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
which has already got a biosimilar to Roche’s Avastin (bevacizumab) cancer drug backed by the FDA. Amgen already has a biosimilar of AbbVie’s Humira (adalimumab) approved in the US ...
and Novartis' Lucentis (ranibizumab), approved biosimilars of those two drugs, and Roche's Vabysmo (faricimab). Compounded bevacizumab formulations are sometimes used to treat wet AMD but ...
Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...
The decreases were primarily due to savings from reduced headcount and lower costs related to biosimilar product ... in combination with toripalimab and bevacizumab. CHS-114 is a highly selective ...
Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures -- UDENYCA® net revenue increased 62% year-over-year -- LOQTORZI® net revenue increased 29% quarter-over-qua ...
JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U ...
OMLYCLO ® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback